- Home
- TIL vs TLSA Comparison
TIL vs TLSA Comparison
Compare TIL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- TLSA
- Stock Information
- Founded
- TIL 2018
- TLSA 2013
- Country
- TIL United States
- TLSA United Kingdom
- Employees
- TIL N/A
- TLSA N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- TLSA Health Care
- Exchange
- TIL Nasdaq
- TLSA Nasdaq
- Market Cap
- TIL 230.1M
- TLSA 187.0M
- IPO Year
- TIL 2021
- TLSA 2000
- Fundamental
- Price
- TIL $23.87
- TLSA $1.44
- Analyst Decision
- TIL Buy
- TLSA
- Analyst Count
- TIL 5
- TLSA 0
- Target Price
- TIL $119.00
- TLSA N/A
- AVG Volume (30 Days)
- TIL 310.5K
- TLSA 193.5K
- Earning Date
- TIL 08-12-2025
- TLSA 07-22-2025
- Dividend Yield
- TIL N/A
- TLSA N/A
- EPS Growth
- TIL N/A
- TLSA N/A
- EPS
- TIL N/A
- TLSA N/A
- Revenue
- TIL N/A
- TLSA N/A
- Revenue This Year
- TIL N/A
- TLSA N/A
- Revenue Next Year
- TIL N/A
- TLSA N/A
- P/E Ratio
- TIL N/A
- TLSA N/A
- Revenue Growth
- TIL N/A
- TLSA N/A
- 52 Week Low
- TIL $9.85
- TLSA $0.63
- 52 Week High
- TIL $92.00
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- TIL 46.54
- TLSA 46.42
- Support Level
- TIL $23.38
- TLSA $1.43
- Resistance Level
- TIL $26.91
- TLSA $1.81
- Average True Range (ATR)
- TIL 3.25
- TLSA 0.09
- MACD
- TIL -0.32
- TLSA -0.02
- Stochastic Oscillator
- TIL 31.75
- TLSA 10.53
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.